1.An Integrated Air Monitoring Approach for Assessment of Formaldehyde in the Workplace.
Stefano DUGHERI ; Alessandro BONARI ; Ilenia POMPILIO ; Marco COLPO ; Nicola MUCCI ; Giulio ARCANGELI
Safety and Health at Work 2018;9(4):479-485
The aim of this study is to validate an integrated air monitoring approach for assessing airborne formaldehyde (FA) in the workplace. An active sampling by silica gel impregnated with 2,4-dinitrophenylhydrazine, a passive solid phase microextraction technique using O-(2,3,4,5,6-pentafluorobenzyl)hydroxylamine as on-fiber derivatization reagent, an electrochemical direct-reading monitor, and an enzyme-based badge were evaluated and tested over a range of 0.020–5.12 ppm, using dynamically generated FA air concentrations. Simple linear regression analysis showed the four methods were suitable for evaluating airborne FA. Personal and area samplings in 12 anatomy pathology departments showed that the international occupational exposure limits in the GESTIS database were frequently exceeded. This monitoring approach would allow a fast, easy-to-use, and economical evaluation of both current work practices and eventual changes made to reduce FA vapor concentrations.
Chromatography
;
Formaldehyde*
;
Humans
;
Linear Models
;
Occupational Exposure
;
Pathology
;
Silica Gel
;
Solid Phase Microextraction
2.Extracorporeal Shock Wave Therapy in Peyronie's Disease: Clinical Efficacy and Safety from a Single-Arm Observational Study
Marina DI MAURO ; Giorgio Ivan RUSSO ; Pier Andrea DELLA CAMERA ; Fabrizio DI MAIDA ; Gianmartin CITO ; Nicola MONDAINI ; Marco CAPECE ; Marco FALCONE ; Francesco SESSA ; Andrea MARI ; Riccardo CAMPI ; Carlotta SABINI ; Sergio SERNI ; Mauro GACCI ; Andrea MINERVINI ; Marco CARINI ; Sebastiano CIMINO ; Girolamo MORELLI ; Andrea COCCI
The World Journal of Men's Health 2019;37(3):339-346
PURPOSE: In this study, we aimed to determine the role of extracorporeal shockwave therapy (ESWT) in the management of Peyronie's disease (PD). MATERIALS AND METHODS: A total of 325 patients suffering from PD were enrolled in this single-arm clinical study. All patients were received ESWT using a schedule of 1 treatment/wk. Penile curvature was measured by a goniometer after intracavernosal drug-induced erection using Alprostadil. Plaque size was measured with a ruler and sexual function assessed by the international index of erectile function (IIEF)-15 score. Severity of erectile dysfunction was classified as severe (IIEF-15 ≤10), moderate (IIEF-15 between 11 and 16), or mild (IIEF-15 between 17 and 25). Results were evaluated at baseline and 3 months after the treatment. RESULTS: All the patients completed the study protocol. Median age was 59.0 years (55.0–64.0 years). After treatment, the median (interquartile range, IQR) plaque size reduced from 1.78 cm2 (1.43–2.17 cm2) to 1.53 cm2 (1.31–1.96 cm2) (p<0.001); the median (IQR) penile length in erection increased from 13.0 cm (12.0–14.0 cm) to 14 cm (13.0–15.0 cm) (p<0.001) and the median (IQR) penile curvature from 30.4° (22.2°–35.4°) to 25.0° (20.2°–30.4°) (p<0.001). We also observed a decrease in pain assessed by visual analogue scale (7 vs. 3; p<0.001), an improvement in each of the IIEF sub-domains (p<0.001) and an improvement in all three PD questionnaire domains (p<0.001). CONCLUSIONS: Based on our findings, ESWT could be considered a safe and efficient minimally invasive option for the management of the patients suffering from PD.
Alprostadil
;
Appointments and Schedules
;
Clinical Study
;
Erectile Dysfunction
;
Humans
;
Male
;
Observational Study
;
Penile Diseases
;
Penile Induration
;
Shock
;
Treatment Outcome
3.How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase Clostridium Histolyticum Therapy?
Andrea COCCI ; Fabrizio DI MAIDA ; Giorgio Ivan RUSSO ; Marina DI MAURO ; Gianmartin CITO ; Marco FALCONE ; Andrea MINERVINI ; Giovanni CACCIAMANI ; Riccardo CAMPI ; Andrea MARI ; Francesco SESSA ; Nicola MONDAINI
The World Journal of Men's Health 2020;38(1):78-84
4.ZNF804A Gene Variants Have a Cross-diagnostic Influence on Psychosis and Treatment Improvement in Mood Disorders
Marco CALABRÒ ; Laura MANDELLI ; Concetta CRISAFULLI ; Marco Di NICOLA ; Roberto COLOMBO ; Luigi JANIRI ; Soo-Jung LEE ; Tae-Youn JUN ; Sheng-Min WANG ; Prakash S. MASAND ; Ashwin A. PATKAR ; Changsu HAN ; Chi-Un PAE ; Alessandro SERRETTI
Clinical Psychopharmacology and Neuroscience 2020;18(2):231-240
Objective:
Genetic variations in the gene encoding zinc finger protein 804A gene (ZNF804A) have been associated with major depression and bipolar disorder. In this work we focused on the potential influence of ZNF804A variations on the risk of developing specific sub-phenotypes as well as the individual response to available treatments.
Methods:
We used two samples of different ethnic origin: a Korean sample, composed by 242 patients diagnosed with major depression and 132 patients diagnosed with bipolar disorder and 326 healthy controls; an Italian sample composed 151 major depression subjects, 189 bipolar disorder subjects and 38 outpatients diagnosed for a primary anxiety disorder.
Results:
Our analyses reported an association of rs1344706 with psychotic phenotype in the cross-diagnostic pooled sample (geno p = 4.15 × 10−4, allelic p = 1.06 × 10−4). In the cross-diagnosis Italian sample but not in the Korean one, rs7597593 was involved with depressive symptoms improvement after treatment (geno p = 0.025, allelic p = 0.007).
Conclusion
The present study evidenced the role of ZNF804A alterations in symptoms improvement after treatment. Both manic and depressive symptoms seem to be modulated by ZNF804A, though the latter was observed in the bipolar pooled sample only. The role of this factor is likely related to synaptic development and maintenance; however, further analyses will be needed to better understand the molecular mechanics involved with ZNF804A.
5.Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases
Domenico De BERARDIS ; Gabriella RAPINI ; Luigi OLIVIERI ; Agostina GIARDINI ; Ida De LAURETIS ; Nicola SERRONI ; Laura ORSOLINI ; Michele FORNARO ; Felice IASEVOLI ; Sabatino TROTTA ; Paolo COTTURA ; Federica VELLANTE ; Marco ALESSANDRINI ; Massimo Di GIANNANTONIO
Clinical Psychopharmacology and Neuroscience 2021;19(1):174-178
Cariprazine is a novel antipsychotic drug that exerts partial agonism of dopamine D2 /D3 receptors with preferential binding to the D 3 receptor, antagonism of 5HT2B receptors, and partial agonism of 5HT1A . Currently, cariprazine has shown clinical efficacy in patients with schizophrenia and with bipolar disorder, as well as adjunctive treatment in patients with Major Depressive Disorder (MDD) and drug-resistant MDD. In the present case series, we report on two patients with treatment-resistant schizophrenia and partial response to clozapine who benefit from combination with cariprazine. The effects of cariprazine combination were remarkable also concerning the adverse metabolic effects of clozapine.